New PET tracer could spot cancers that standard scans overlook

NCT ID NCT07118176

Ongoing Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tracer behaves in the body and whether it can help detect cancers that standard FDG-PET scans might miss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gallium Ga 68 FAPi-46
What this could lead to: If successful, this tracer could improve cancer detection and help doctors see tumors that standard scans might miss.
What could go wrong: This is an early phase 1 study with only 30 participants, so results may not apply broadly. The tracer may not highlight all cancer types effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal gland cancer anal carcinoma anus neoplasm brain cancer breast carcinoma breast neoplasm cancer cancer of unknown primary site carcinoma of esophagus Carcinoma, Medullary cervical carcinoma cholangiocarcinoma colorectal carcinoma colorectal neoplasm Esophageal Neoplasms gastric carcinoma gastric neoplasm head and neck carcinoma hematopoietic and lymphoid system neoplasm hepatocellular carcinoma lung carcinoma lung neoplasm medullary thyroid gland carcinoma neuroendocrine neoplasm ovarian cancer ovarian carcinoma pancreatic adenocarcinoma pancreatic neoplasm penile carcinoma penile neoplasm primary peritoneal carcinoma prostate cancer prostate carcinoma salivary gland cancer salivary gland carcinoma sarcoma skin carcinoma solitary fibrous tumor testicular cancer thymic carcinoma thyroid gland carcinoma Thyroid Neoplasms transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma uterine cancer Uterine Cervical Neoplasms vaginal cancer vaginal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAL CARCINOMA BLADDER CARCINOMA BREAST CARCINOMA CERVICAL CARCINOMA CHOLANGIOCARCINOMA COLORECTAL CARCINOMA ESOPHAGEAL CARCINOMA GASTRIC CARCINOMA HEAD AND NECK CARCINOMA HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM HEPATOCELLULAR CARCINOMA LUNG CARCINOMA MALIGNANT ADRENAL GLAND NEOPLASM MALIGNANT BRAIN NEOPLASM MALIGNANT NEOPLASM OF UNKNOWN PRIMARY MALIGNANT SOLID NEOPLASM MALIGNANT TESTICULAR NEOPLASM MALIGNANT UTERINE NEOPLASM NEUROENDOCRINE NEOPLASM OVARIAN CARCINOMA PANCREATIC CARCINOMA PENILE CARCINOMA PLEURAL CARCINOMATOSIS PRIMARY PERITONEAL CARCINOMA PROSTATE CARCINOMA SALIVARY GLAND CARCINOMA SARCOMA SKIN CARCINOMA SOLITARY FIBROUS TUMOR THYMUS CARCINOMA THYROID GLAND CARCINOMA THYROID GLAND MEDULLARY CARCINOMA UROTHELIAL CARCINOMA VAGINAL CARCINOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.